BioXcel has added another big name to its list of clients. Takeda is the latest company to sign up to work with BioXcel, a database-driven drug discovery shop that already boasts relationships with Alexion, Sanofi, Teva and Vertex.
Feedback from an early-access program for Synthetic Genomics' personal DNA workstation has started to emerge. And the initial news is positive, with a researcher at the University of California, San Francisco, reporting that the device is cutting the time and money it takes to synthesize DNA.
Scientists at Zoetis' new Centre for Digital Innovation are working on apps and other technologies to improve both livestock production and companion-animal health, and Zoetis has launched the initiative with an ambitious goal: to create an electronic health record for every farm animal in the U.K.
In a win for HIV vaccine research, Duke University researchers have scored $20 million in grants from the National Institutes of Health to develop an HIV vaccine.
Pfizer has a new vaccines R&D head in Kathrin Jansen, who will begin at the post on June 1. Previously CSO of Pfizer's vaccine research and early development, Jansen will report to global R&D president Mikael Dolsten and work out of Pfizer's Pearl River, New York research site.
As the industry turns its attention to low-cost, easy-to-use diagnostics for developing countries, researchers at Florida Atlantic University are developing a biosensing tool that uses a smartphone and a paper microchip to screen for diseases such as HIV.
In the wake of its multibillion-dollar asset swap with Novartis, GlaxoSmithKline is doubling down on its vaccines focus. And it'll be doing that in Maryland, where it's establishing a new global R&D center.
UPenn researchers are in the early stage of developing a neural implant to help the 10 million people across the globe with traumatic brain injury improve their memory.
At the Children's Hospital of Philadelphia, researchers are looking toward biodegradable nanoparticles capable of delivering cancer drugs to neuroblastoma without harming surrounding tissue.
New York City's Anterios is developing ANT-1207, a lotion containing the active ingredient of Botox (marketed by recently acquired Allergan) that can be applied on the skin via a 10-minute massage. Anterios recently filed for a $58 million IPO with the Securities and Exchange Commission.